Homburger advised Vifor Pharma

Vifor Pharma and Angion Biomedica Corp. announced the signing of a licensing agreement for the commercialization of Angion’s ANG-3777 molecule developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). Under the terms of the agreement, Vifor Pharma has been granted an exclusive license for commercializing ANG-3777 nephrology indications worldwide except Greater China. Further, Vifor Pharma has, apart from upfront, clinical and commercial milestone payments as well as royalty payments, agreed to a considerable equity investment in Angion.

The team

Homburger acted as legal counsel to Vifor in connection with the legal due diligence review of Angion’s development activities and the drafting, negotiation and final documentation of the license agreement. The team was led by partner Georg Rauber (IP / IT – pictured) and included associates Carola Winzeler (IP / IT), Valentin Fluor (IP / IT; Corporate / M&A) and junior associate Emily Zurfluh.

Homburger advised Vifor Pharma

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram